Business · 01/08/2022Updated: 10/17/2026 · 1 min read
Lupin Pharmaceuticals, Inc., et al. Withdraw FDA Approval of Seven Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has withdrawn the approval of seven abbreviated new drug applications (ANDAs) from multiple applicants, following written notifications that the drug products were no longer in market.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →